Myovant Sciences to Present at Upcoming Investor Conferences
SVB Leerink 10th Annual Global Healthcare Conference onFebruary 25, 2021 at3:40 p.m. Eastern Time .David Marek , Chief Executive Officer ofMyovant Sciences, Inc. , andFrank Karbe , President and Chief Financial Officer ofMyovant Sciences, Inc. , will participate in a fireside chat. Management will also participate in one-on-one investor meetings onFebruary 25 .- Cowen 41st Annual
Health Care Conference onMarch 2, 2021 at11:10 a.m. Eastern Time .Mr. Marek andMr. Karbe will participate in a fireside chat. Management will also participate in one-on-one investor meetings onMarch 2 .
The presentations will be accessible on the Events page under the Investors & Media section of the
About Myovant Sciences
Myovant Sciences aspires to redefine care for women and for men through purpose-driven science, empowering medicines, and transformative advocacy. We have one FDA-approved medicine, ORGOVYX™ (relugolix), for adult patients with advanced prostate cancer. Our lead product candidate, relugolix combination tablet (relugolix 40 mg, estradiol 1.0 mg, and norethindrone acetate 0.5 mg), is under regulatory review in Europe and the U.S. for women with uterine fibroids and is under development for women with endometriosis. We are also developing MVT-602, an oligopeptide kisspeptin-1 receptor agonist, which has completed a Phase 2a study for female infertility as part of assisted reproduction. Sumitovant Biopharma, Ltd., a wholly owned subsidiary of Sumitomo Dainippon Pharma Co., Ltd., is our majority shareholder. For more information, please visit our website at www.myovant.com. Follow @Myovant on Twitter and LinkedIn.
Investor Contact:
Vice President, Investor Relations
+1 (650) 781-9106
investors@myovant.com
Media Contact:
Albert Liao
Director, Corporate Communications
+1 (650) 410-3055
media@myovant.com
Source: Myovant Sciences, Inc.